This stock is no longer traded. It was delisted on June 29, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Assertio Holdings Inc. is a leading commercial pharmaceutical company that brings differentiated branded prescription products to patients across key therapeutic areas. It maintains a robust portfolio focused on neurology, inflammation, pain management, oncology, and hospital products, including medications such as INDOCIN for treating rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, gouty arthritis, and acute painful shoulder; Sympazan, a benzodiazepine for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome; Otrexup, SPRIX, CAMBIA, and Zipsor; as well as Rolvedon in oncology following strategic business development. The company specializes in acquiring, licensing, and optimizing commercial-stage assets through an acquisition-driven model, emphasizing targeted marketing and lifecycle management to serve patients primarily in the United States. Founded in 1995 and headquartered in Lake Forest, Illinois, Assertio Holdings Inc. plays a vital role in the specialty pharmaceuticals sector by providing established, high-margin products in neuroscience, immunology, and oncology.
Website100 South Saunders Road
Lake Forest, IL, 60045
United States
Summary of May 13's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
Summary of May 4's posts. Generated by AI.
Investors talking about ASRT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.